Perceptive Advisors
Latest statistics and disclosures from Perceptive Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ACLX, NUVL, FOLD, IOVA, PCVX, and represent 29.85% of Perceptive Advisors's stock portfolio.
- Added to shares of these 10 stocks: VRNA (+$126M), VKTX (+$62M), ARGX (+$56M), NUVL (+$44M), CNTA (+$38M), XBI (+$37M), PODD (+$33M), Oruka Therapeutics (+$30M), AXSM (+$29M), VRDN (+$27M).
- Started 15 new stock positions in DYN, ROIV, PODD, EXAS, PYXS, LXEO, Zenas Biopharma, Oruka Therapeutics, Adagio Med Hldgs, KYMR. TIL, Forte Biosciences, FULC, AMLX, XNCR.
- Reduced shares in these 10 stocks: CERE (-$441M), MDGL (-$74M), NBIX (-$50M), NTRA (-$39M), CRNX (-$38M), ADMA (-$34M), BBIO (-$31M), SWTX (-$31M), MDT (-$22M), CGEM (-$13M).
- Sold out of its positions in AXGN, BBIO, CABA, CERE, CGEM, EGRX, ENGN, FHTX, FBRX, KALV. MDGL, RXRX, RVNC, SPRY, SKYE, TCMD, TEM, VBIVQ.
- Perceptive Advisors was a net seller of stock by $-149M.
- Perceptive Advisors has $4.7B in assets under management (AUM), dropping by 13.85%.
- Central Index Key (CIK): 0001224962
Tip: Access up to 7 years of quarterly data
Positions held by Perceptive Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 106 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Arcellx Common Stock (ACLX) | 6.9 | $325M | 3.9M | 83.51 |
|
|
| Nuvalent Inc-a (NUVL) | 6.4 | $305M | +16% | 3.0M | 102.30 |
|
| Amicus Therapeutics (FOLD) | 6.3 | $300M | 28M | 10.68 |
|
|
| Iovance Biotherapeutics (IOVA) | 5.3 | $250M | +2% | 27M | 9.39 |
|
| Vaxcyte (PCVX) | 4.9 | $232M | +8% | 2.0M | 114.27 |
|
| Verona Pharma Sponsored Ads (VRNA) | 4.1 | $196M | +180% | 6.8M | 28.77 |
|
| Rhythm Pharmaceuticals (RYTM) | 3.9 | $187M | +3% | 3.6M | 52.39 |
|
| Soleno Therapeutics (SLNO) | 3.4 | $162M | 3.2M | 50.49 |
|
|
| Intra Cellular Therapies (ITCI) | 2.5 | $119M | -5% | 1.6M | 73.17 |
|
| Apogee Therapeutics (APGE) | 2.5 | $118M | -4% | 2.0M | 58.74 |
|
| Viking Therapeutics (VKTX) | 2.3 | $108M | +135% | 1.7M | 63.31 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.1 | $101M | +59% | 6.3M | 15.99 |
|
| Immatics SHS (IMTX) | 2.0 | $92M | 8.1M | 11.41 |
|
|
| Evolus (EOLS) | 1.8 | $87M | -6% | 5.4M | 16.20 |
|
| Spyre Therapeutics Com New (SYRE) | 1.8 | $85M | -5% | 2.9M | 29.41 |
|
| CryoLife (AORT) | 1.6 | $74M | 2.8M | 26.62 |
|
|
| Biohaven (BHVN) | 1.6 | $74M | 1.5M | 49.97 |
|
|
| Astria Therapeutics (ATXS) | 1.5 | $71M | 6.5M | 11.01 |
|
|
| Axsome Therapeutics (AXSM) | 1.5 | $70M | +70% | 783k | 89.87 |
|
| Applied Therapeutics (APLT) | 1.4 | $68M | 8.0M | 8.50 |
|
|
| Cargo Therapeutics (CRGX) | 1.4 | $68M | 3.7M | 18.45 |
|
|
| Immunovant (IMVT) | 1.4 | $68M | +12% | 2.4M | 28.51 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.4 | $67M | +55% | 1.2M | 57.54 |
|
| Argenx Se Sponsored Adr (ARGX) | 1.4 | $64M | +661% | 119k | 542.08 |
|
| Miragen Therapeutics (VRDN) | 1.4 | $64M | +72% | 2.8M | 22.75 |
|
| Edgewise Therapeutics (EWTX) | 1.3 | $62M | +25% | 2.3M | 26.69 |
|
| Protagonist Therapeutics (PTGX) | 1.3 | $62M | +8% | 1.4M | 45.00 |
|
| Meiragtx Holdings (MGTX) | 1.1 | $52M | +11% | 13M | 4.17 |
|
| Aldeyra Therapeutics (ALDX) | 1.1 | $50M | 9.3M | 5.39 |
|
|
| Akero Therapeutics (AKRO) | 1.0 | $49M | +14% | 1.7M | 28.69 |
|
| Solid Biosciences Com New (SLDB) | 1.0 | $48M | 6.9M | 6.97 |
|
|
| Tarsus Pharmaceuticals (TARS) | 0.9 | $43M | 1.3M | 32.89 |
|
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 0.8 | $40M | +1664% | 400k | 98.80 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.8 | $38M | 5.4M | 7.00 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.8 | $37M | -50% | 725k | 51.10 |
|
| Nautilus Biotechnology (NAUT) | 0.8 | $36M | 13M | 2.85 |
|
|
| Celcuity (CELC) | 0.7 | $35M | 2.4M | 14.91 |
|
|
| Insulet Corporation (PODD) | 0.7 | $33M | NEW | 142k | 232.75 |
|
| Oruka Therapeutics | 0.6 | $30M | NEW | 1.2M | 24.51 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.6 | $29M | -3% | 1.5M | 19.14 |
|
| Ocular Therapeutix (OCUL) | 0.6 | $29M | 3.3M | 8.70 |
|
|
| Intuitive Surgical Com New (ISRG) | 0.6 | $29M | -5% | 58k | 491.27 |
|
| Natera (NTRA) | 0.6 | $28M | -58% | 220k | 126.95 |
|
| Cg Oncology (CGON) | 0.6 | $28M | 734k | 37.73 |
|
|
| Zymeworks Del (ZYME) | 0.6 | $27M | +30% | 2.2M | 12.55 |
|
| Dyne Therapeutics (DYN) | 0.5 | $26M | NEW | 718k | 35.92 |
|
| Adagio Med Hldgs | 0.5 | $25M | NEW | 9.8M | 2.58 |
|
| Arvinas Ord (ARVN) | 0.5 | $25M | 1.0M | 24.63 |
|
|
| Procept Biorobotics Corp (PRCT) | 0.5 | $25M | +49% | 316k | 80.12 |
|
| Neurocrine Biosciences (NBIX) | 0.5 | $25M | -67% | 212k | 115.22 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.5 | $24M | +80% | 4.6M | 5.14 |
|
| Instil Bio Com New (TIL) | 0.5 | $23M | NEW | 346k | 67.32 |
|
| Livanova SHS (LIVN) | 0.5 | $23M | -3% | 429k | 52.54 |
|
| Springworks Therapeutics (SWTX) | 0.5 | $22M | -58% | 692k | 32.04 |
|
| Medtronic SHS (MDT) | 0.5 | $22M | -50% | 245k | 90.03 |
|
| Adma Biologics (ADMA) | 0.4 | $21M | -61% | 1.1M | 19.99 |
|
| Xenon Pharmaceuticals (XENE) | 0.4 | $21M | -10% | 525k | 39.37 |
|
| Zenas Biopharma | 0.4 | $19M | NEW | 1.1M | 16.92 |
|
| Disc Medicine (IRON) | 0.4 | $19M | -30% | 387k | 49.14 |
|
| Rocket Pharmaceuticals (RCKT) | 0.4 | $17M | -25% | 932k | 18.47 |
|
| Inhibrx Biosciences (INBX) | 0.4 | $17M | 1.1M | 15.66 |
|
|
| Rapport Therapeutics (RAPP) | 0.3 | $15M | 748k | 20.48 |
|
|
| Merus N V (MRUS) | 0.3 | $15M | 300k | 49.96 |
|
|
| Insmed Com Par $.01 (INSM) | 0.3 | $13M | 180k | 73.00 |
|
|
| Icon SHS (ICLR) | 0.3 | $13M | +41% | 44k | 287.31 |
|
| Arcutis Biotherapeutics (ARQT) | 0.3 | $13M | -12% | 1.4M | 9.30 |
|
| Pepgen (PEPG) | 0.3 | $12M | 1.4M | 8.55 |
|
|
| Tyra Biosciences (TYRA) | 0.3 | $12M | -49% | 511k | 23.51 |
|
| Xencor (XNCR) | 0.2 | $11M | NEW | 528k | 20.11 |
|
| Verrica Pharmaceuticals (VRCA) | 0.2 | $10M | 7.1M | 1.45 |
|
|
| Roivant Sciences SHS (ROIV) | 0.2 | $9.8M | NEW | 848k | 11.54 |
|
| Arrivent Biopharma (AVBP) | 0.2 | $9.8M | 415k | 23.50 |
|
|
| EXACT Sciences Corporation (EXAS) | 0.2 | $8.5M | NEW | 125k | 68.12 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $8.3M | +62% | 1.0M | 7.99 |
|
| Allogene Therapeutics (ALLO) | 0.2 | $7.6M | 2.7M | 2.80 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $6.9M | NEW | 2.1M | 3.24 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.1 | $5.8M | -55% | 256k | 22.63 |
|
| Female Health (VERU) | 0.1 | $5.6M | +3% | 7.3M | 0.77 |
|
| Cassava Sciences Put Option (SAVA) | 0.1 | $5.4M | 183k | 29.43 |
|
|
| Fulcrum Therapeutics Call Option (FULC) | 0.1 | $5.4M | NEW | 1.5M | 3.57 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.1 | $5.2M | 500k | 10.45 |
|
|
| Biodesix (BDSX) | 0.1 | $3.9M | 2.2M | 1.78 |
|
|
| Precision Biosciences Com New (DTIL) | 0.1 | $3.8M | 426k | 8.96 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.1 | $3.4M | -34% | 816k | 4.11 |
|
| Lyra Therapeutics (LYRA) | 0.1 | $3.3M | 13M | 0.26 |
|
|
| Nanobiotix Sponsored Ads (NBTX) | 0.1 | $3.2M | 555k | 5.75 |
|
|
| Absci Corp (ABSI) | 0.1 | $2.7M | 700k | 3.82 |
|
|
| Athira Pharma (ATHA) | 0.1 | $2.4M | 5.4M | 0.45 |
|
|
| X4 Pharmaceuticals (XFOR) | 0.1 | $2.4M | 3.5M | 0.67 |
|
|
| Envveno Medical (NVNO) | 0.0 | $2.3M | +11% | 694k | 3.36 |
|
| Kymera Therapeutics (KYMR) | 0.0 | $2.2M | NEW | 46k | 47.33 |
|
| Trinity Biotech Spons Adr New (TRIB) | 0.0 | $2.0M | 1.8M | 1.10 |
|
|
| Pyxis Oncology Common Stock (PYXS) | 0.0 | $1.9M | NEW | 509k | 3.67 |
|
| Irhythm Technologies (IRTC) | 0.0 | $1.7M | -35% | 23k | 74.24 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.0 | $1.5M | 35k | 43.89 |
|
|
| Lexeo Therapeutics (LXEO) | 0.0 | $1.3M | NEW | 140k | 9.04 |
|
| Novavax Com New Put Option (NVAX) | 0.0 | $1.3M | 100k | 12.63 |
|
|
| Fate Therapeutics (FATE) | 0.0 | $1.2M | 346k | 3.50 |
|
|
| Singular Genomics Systems In Com New (OMIC) | 0.0 | $798k | -28% | 51k | 15.67 |
|
| Kyverna Therapeutics (KYTX) | 0.0 | $734k | 150k | 4.89 |
|
|
| Forte Biosciences Com New | 0.0 | $535k | NEW | 96k | 5.59 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.0 | $251k | 117k | 2.15 |
|
|
| Caremax Cl A New (CMAX) | 0.0 | $170k | -18% | 100k | 1.70 |
|
| Revolution Medicines *w Exp 12/17/202 (RVMDW) | 0.0 | $35k | 250k | 0.14 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.7k | 167k | 0.01 |
|
|
| Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $594.000000 | 60k | 0.01 |
|
Past Filings by Perceptive Advisors
SEC 13F filings are viewable for Perceptive Advisors going back to 2010
- Perceptive Advisors 2024 Q3 filed Nov. 14, 2024
- Perceptive Advisors 2024 Q2 restated filed Aug. 16, 2024
- Perceptive Advisors 2024 Q2 filed Aug. 14, 2024
- Perceptive Advisors 2024 Q1 restated filed Aug. 6, 2024
- Perceptive Advisors 2024 Q1 filed May 15, 2024
- Perceptive Advisors 2023 Q4 restated filed Feb. 26, 2024
- Perceptive Advisors 2023 Q4 filed Feb. 14, 2024
- Perceptive Advisors 2023 Q3 filed Nov. 14, 2023
- Perceptive Advisors 2023 Q2 restated filed Aug. 24, 2023
- Perceptive Advisors 2023 Q2 filed Aug. 14, 2023
- Perceptive Advisors 2023 Q1 restated filed May 16, 2023
- Perceptive Advisors 2023 Q1 filed May 15, 2023
- Perceptive Advisors 2022 Q4 filed Feb. 14, 2023
- Perceptive Advisors 2022 Q3 filed Nov. 14, 2022
- Perceptive Advisors 2022 Q2 filed Aug. 15, 2022
- Perceptive Advisors 2022 Q1 filed May 16, 2022